

C1  
cont  
sub  
D3  
16. (Amended) A method comprising the step of isolating a variant of keratinocyte growth factor-2 (KGF-2) from a host cell containing a polynucleotide of Claim 10 cultured under conditions allowing the expression of the variant of KGF-2 by said host cell.

C2  
sub  
D3  
18. (Amended) A method comprising the steps of:  
(a) culturing a prokaryotic or eukaryotic host cell containing a polynucleotide of Claim 10; and  
(b) maintaining said host cell under conditions allowing the expression of a variant of keratinocyte growth factor-2 (KGF-2) by said host cell.

sub  
D3  
C3  
21. (Amended) A pharmaceutical composition comprising a variant of keratinocyte growth factor-2 (KGF-2) isolated in accordance with the method of Claim 26 in association with a pharmaceutically acceptable vehicle.

22. (Amended) A pharmaceutical composition comprising a variant of keratinocyte growth factor-2 (KGF-2) isolated in accordance with the method of Claim 27 in association with a pharmaceutically acceptable vehicle.

C4  
sub  
D3  
25. (Amended) A variant of keratinocyte growth factor-2 (KGF-2) selected from the group of amino acid sequences consisting of methionylated or non-methionylated  $\text{NH}_2\text{-His-Val-Arg-Ser-Tyr-[Asn}^{71}\text{-Ser}^{208}\text{]-COOH}$ .

Please add the following new claims 26 and 27:

C5  
sub  
D3  
26. The method of Claims 13, 14 or 15 further comprising isolating a variant of keratinocyte growth factor-2 from said cultured cells or said nutrient medium.

27. The method of Claim 18, further comprising after step (b) the following step (c):  
(c) isolating the variant of KGF-2 expressed by said host cell.